author-photo

Victoria Zazulina

Boehringer Ingelheim

28

Papers

5892

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

First-Line afatinib versus chemotherapy in patients with non–small cell lung cancer and common epidermal growth factor receptor gene mutations and brain metastases

2016 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial

2016
Show All
- Source
- Cite
- Save
Citations (0)
First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases

2016 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (215)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

2015 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (1033)
Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

2015
Show All
- Source
- Cite
- Save
Citations (0)
Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (66)
Epidermal Growth Factor Receptor (EGFR)-Mediated Adverse Events (AEs) in Patients (pts) With EGFR-Mutation Positive (EGFR M+) Non-Small Cell Lung Cancer (NSCLC) Treated With Afatinib (A)

2014 International Journal of Radiation Oncology Biology Physics
Show All
- Source
- Cite
- Save
Citations (0)
Analysis of overall survival (OS) in two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut)

2014 European Respiratory Journal
Show All
- Source
- Cite
- Save
Citations (6)
Cell Lung Cancer (NSCLC) Treated with Afatinib

2013
Show All
- Source
- Cite
- Save
Citations (0)
LUX-Lung 6: Patient-reported outcomes (PROs) from a randomized open-label, phase III study in first-line advanced NSCLC patients (pts) harboring epidermal growth factor receptor (EGFR) mutations.

2013 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (15)